Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)

Osaka, Japan, October 29, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK[1]) (“Takeda”) announced today, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2021, as below.

 

  1. Revised Forecast for Full Year Consolidated Financials for the Fiscal Year Ending March 31, 2021

 
 (millions of yen)

Revenue

Core
Operating
Profit

Operating
profit

Profit before
income taxes

Net profit attributable
to owners of the Company

Basic earnings
per share

Core EPS

Previous Forecast (A)*

3,250,000

984,000

395,000

230,000

92,000

58.91 yen

420 yen

Revised Forecast (B)

3,200,000

984,000

434,000

258,000

124,000

79.39 yen

420 yen

Discrepancy (B-A)

-50,000

+39,000

+28,000

+32,000

Change %

-1.5%

+9.9%

+12.2%

+34.8%

* Announced on July 31, 2020.

  1. Reasons for Revision

The revenue forecast has been decreased by 50.0 billion JPY, or 1.5%, versus the previous forecast to 3,200.0 billion JPY. This is mainly due to changes in the assumptions of foreign exchange rates reflecting the trend towards appreciation of the yen.

The Operating Profit forecast has been increased by 39.0 billion JPY, or 9.9%, to 434.0 billion JPY. This reflects assumptions for one-time gains from several announced divestitures that were not included in the previous forecast but are now expected to be recognized within the current fiscal year, with the exception of the sale of shareholdings in Takeda Consumer Healthcare Company Limited*1. These divestiture gains are non-recurring items and unrelated to our ongoing operations, and therefore do not affect our Core Operating Profit forecast, which remains unchanged at 984.0 billion JPY. Although there is a negative impact to Core Operating Profit from foreign exchange rate fluctuations, this is expected to be absorbed by business momentum underpinned by cost synergies and efficiencies.

The net profit for the period attributable to owners of the Company forecast has been increased by 32.0 billion JPY, or 34.8%, to 124.0 billion JPY, primarily due to the increase in profit before tax and updated tax rate assumptions.

1 2 3 4 5

Share